Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

MannKind shares slide 22% as FDA delays review of Tyvaso DPI new drug application

By Brian Buntz | February 24, 2022

Mannkind/United TherapeuticsInhalable insulin specialist MannKind Corp. (NASDAQ:MNKD) announced that the FDA is extending its deadline to review United Therapeutics’ (NASDAQ:UTHR) new drug application (NDA) for Tyvaso DPI from February to May.

MannKind is developing Tyvaso DPI (treprostinil) in collaboration with United Therapeutics.

The drug candidate Tyvaso DPI would potentially treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

MNKD shares fell 22.54% to $2.84 in afternoon trading, while UTHR shares dipped 13.81% to $166.45.

FDA has asked for additional information about the pulmonary safety of Tyvaso DPI related to a pending citizen petition filed in July 2021. The petition questions the safety of fumaryl diketopiperazine (FDKP), an excipient used in Tyvasson DPI. The excipient is also used in MannKind’s inhalable insulin product Afrezza.

The petition requests that FDA require additional testing of FDKP, which it describes as an “irritant” potentially associated with “a serious risk of acute bronchospasm in patients with chronic lung disease, such as asthma and chronic obstructive pulmonary disease.”

On Oct. 15, 2021, the FDA issued a complete response letter for Tyvaso DPI outlining its decision to decline approval of the NDA at that time based on an open inspection problem associated with third-party testing of the treprostinil drug substance.

FDA approved an inhalation solution form of Tyvaso in 2009. An indication followed in 2021 for the treatment of pulmonary hypertension associated with interstitial lung disease.


Filed Under: Pulmonology
Tagged With: MannKind, Tyvaso DPI, United Therapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Janssen
Janssen reports positive clinical trial data for its Xarelto to treat PAD effects
IPF
4 potential pulmonary fibrosis therapies to watch
TFF
TFF Pharmaceuticals sees promise in Phase 1 trial of inhaled tacrolimus powder for lung transplant
Aria Pharmaceuticals
Why Aria Pharmaceuticals is upbeat about two novel IPF treatment candidates 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50